Innovent Biologics IPO Valuation: Surprisingly Grounded in Reality
Innovent Biologics Inc (1641475D HK) launched its Hong Kong IPO today. The mid-point of Innovent's IPO price range of HK$12.50-14.00 per share...
863 Views
ECM Weekly (13 October 2018) -Ā Tencent Music Delays IPO
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
838 Views
Innovent Biologics (äæ”č¾¾ēē©) IPO:Ā Pricing the PD-1 and Biosimilars Competition (Part 2)
Innovent Biologics, a leading biologics company in China, is raising up to USDĀ 500 million to list in Hong Kong. In our previous insight (link...
741 Views
Innovent Biologics IPO Preview: Limited Upside on China's PD-1 Drug Market Compared to BeiGene
Innovent Biologics Inc (1641475D HK)Ā is the fourth pre-profit biotech firm to IPO in Hong Kong since Ascletis Pharma Inc (1672 HK), BeiGene Ltd...
853 Views
ECM Weekly (29 September 2018) - China Renaissance's First-Day Return Is the Worst in 2018
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
627 Views